Izokibep

Summary

Izokibep (CHEMBL4297686) is a phase-3 clinical-stage protein; indicated across 5 conditions including hidradenitis suppurativa and psoriasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 5 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297686
Name	Izokibep
Type	Protein
Max phase	3

Also known as: Aby-035, ABY-035, Aby-035/afo2, Aby035, IMG-020, Izokibep, IZOKIBEP

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hidradenitis suppurativa	3	MONDO:0006559	EFO:1000710
psoriasis	2	MONDO:0005083	EFO:0000676
psoriatic arthritis	2	MONDO:0011849	EFO:0003778
ankylosing spondylitis	2	MONDO:0005306	EFO:0003898
uveitis	2	MONDO:0020283	EFO:1001231

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	6
PHASE1	2
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05623345	PHASE2/PHASE3	TERMINATED	Psoriatic Arthritis Study of Izokibep
NCT05905783	PHASE3	TERMINATED	Hidradenitis Suppurativa Study of Izokibep
NCT03591887	PHASE2	COMPLETED	A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
NCT04706741	PHASE2	COMPLETED	A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
NCT04713072	PHASE2	COMPLETED	A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
NCT04795141	PHASE2	TERMINATED	ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
NCT05355805	PHASE2	COMPLETED	Hidradenitis Suppurativa Phase 2b Study of Izokibep
NCT05384249	PHASE2	TERMINATED	Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
NCT02690142	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035
NCT03580278	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).